Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
!!Link opens in a new tab
!!Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Targeting Angiogenesis in Colorectal Carcinoma
Anthony Lopez
, Kazuto Harada
, Maria Vasilakopoulou
, Namita Shanbhag
,
Jaffer A. Ajani
Cancer Prevention Training Program
GI Medical Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
70
!!Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting Angiogenesis in Colorectal Carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Angiogenesis
100%
Antiangiogenic Agents
100%
Bevacizumab
100%
Colorectal Carcinoma
100%
Signaling Network
50%
Clinically Significant
50%
Vascular Endothelial Growth Factor
50%
Chemotherapy
50%
Colorectal Cancer
50%
Vascular Permeability
50%
Prognostic Biomarker
50%
Mitogenesis
50%
Clinical Trials
50%
Treatment Strategy
50%
Drug Target
50%
Second-line Therapy
50%
First-line Therapy
50%
Prospective Randomized Trial
50%
Antiangiogenic
50%
Maintenance Treatment
50%
Survival Migration
50%
Endothelial Viability
50%
Antiangiogenic Therapy
50%
Multiple Signals
50%
Receptor Tyrosine Kinase Inhibitor
50%
Armamentarium
50%
Ramucirumab
50%
Neoangiogenesis
50%
Multiple Receptor
50%
Colorectal Cancer Prognosis
50%
Sequence of Therapy
50%
Aflibercept
50%
Biosimilar
50%
Family Proteins
50%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Angiogenesis Inhibitor
66%
Bevacizumab
66%
Vasculotropin
33%
Protein Tyrosine Kinase
33%
Protein Tyrosine Kinase Inhibitor
33%
Clinical Trial
33%
Biological Marker
33%
Receptor
33%
Antiangiogenic
33%
Drug Delivery System
33%
Cancer Prognosis
33%
Antiangiogenic Therapy
33%
Ramucirumab
33%
Biosimilar Agent
33%
Aflibercept
33%
Chemotherapy Regimen
33%